Ionis Pharmaceuticals IONS Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's deferred revenue, net of current portion?
- Ionis Pharmaceuticals (IONS) reported deferred revenue, net of current portion of $75.75M in Q1 2026.
- How has Ionis Pharmaceuticals's deferred revenue, net of current portion changed year-over-year?
- Ionis Pharmaceuticals's deferred revenue, net of current portion decreased by 46.2% year-over-year, from $140.68M to $75.75M.
- What is the long-term trend for Ionis Pharmaceuticals's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's deferred revenue, net of current portion has grown at a -26.3% compound annual growth rate (CAGR), from $424.05M to $92M.